Daol Investment & Securities on the 13th raised its target price for HK Inno.N from 65,000 won to 70,000 won, saying it expects continued domestic and overseas sales growth of K-CAB, its treatment for gastroesophageal reflux disease. It maintained its investment rating of "Buy."


[Click-e Stock] "HK Inno.N, K-CAB Global Expansion... Target Price Up" View original image

Lee Jisoo, an analyst at Daol Investment & Securities, said, "With the completion of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and the securing of meaningful Phase 3 clinical results, the possibility of additional license-out (L/O) deals, including in Europe, is emerging," adding, "When valuing the new drug, we raised the probability of clinical success from the previous 60% to 90%, and accordingly increased the fair value per share to 70,000 won."


In the fourth quarter of last year, HK Inno.N posted sales of 291.9 billion won, up 23.8% year-on-year, and operating profit of 40.1 billion won, up 64.5% year-on-year. The operating profit margin (OPM) was 13.7%, in line with the market consensus (the average of securities firms' forecasts). K-CAB recorded sales of 52.6 billion won, a 19.1% year-on-year increase, driven by higher domestic and overseas sales. In particular, in China, prescriptions increased thanks to the full-scale inclusion in the reimbursement list and greater brand awareness, leading to royalty income of about 5 billion won, double the level of a year earlier. Revenue recognition of 20 billion won from Comirnaty (Pfizer's COVID-19 vaccine) and the earnings recovery of the Health & Beauty (H&B) division also contributed to meeting market expectations.


Results are expected to improve further in 2026. Lee analyzed, "With infusion solution sales continuing to recover following the end of the doctors' strike, we expect growth in prescriptions of Avastin (anticancer drug), Dapain (diabetes treatment), and K-CAB, as well as an increase in royalty revenue from China." Accordingly, 2026 sales are estimated at 1.1394 trillion won, up 7.2% from the previous year, and operating profit at 124.7 billion won, up 12.4% (OPM 10.9%).



The potential for K-CAB to enter the U.S. market is also drawing attention. The NDA has already been filed with the FDA, and approval is expected in the near term. In China, K-CAB has been recognized as a Class 1 drug (China original innovative drug) and is evaluated as the product with the highest preference among healthcare professionals. Lee stressed, "Even amid intensifying competition in oral formulations, the partner company's ongoing Phase 2 clinical trial of the injectable formulation is laying the foundation for mid- to long-term growth."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing